

LaVoie Group Newsletter

The Acknowledged Leader in Life Science Communications

WINTER 2007

In This Issue

2008 Life Sciences Events Planning Calendar Launched

LaVoie Group Selected by The GI Company as Agency of Record

LaVoie Group to Attend JP Morgan's Annual Healthcare Conference Jan. 7-10, 2008

Donna LaVoie to Chair Panel Discussion at BIO 2008

Quick Links

[Fact Sheet](#)
[Case Studies](#)

Happy Holidays from LaVoie Group:

This time of year can be so busy and planning next year's activities can be like trying to hit a moving target. As the new year approaches, it is time to consider your strategic communications objectives and activities for 2008.

LaVoie Group invites you to take advantage of our Strategy and Planning Workshop, designed to identify opportunities to maximize the impact of your public, investor and corporate communications programs.

For more information on this workshop or a potential partnership with LaVoie Group, please contact us at 978.745.4200 x103 or dlavoie@lavoiegroup.com.

Sincerely,



Donna L. LaVoie
President & CEO

2008 Life Sciences Events Planning Calendar Launched

LaVoie Group has launched its 2008 Life Sciences Events Planning Calendar. This valuable calendar features key industry events, including medical, partnering and investor meetings. To view LaVoie Group's Life Sciences Events Planning Calendar, please click [here](#).

LaVoie Group Selected by The GI Company as Agency of Record

LaVoie Group, a life sciences focused, corporate, investor and public relations firm has added The GI Company, of Framingham, MA, to its client roster.

Donna LaVoie, President and CEO, commented, "The GI Company specializes in developing drugs for gastrointestinal and related diseases. This is a company with a rich pipeline and a compendium of data to be released in 2008. We are delighted to be working with them."

About The GI Company

The GI Company is a clinical-stage biotechnology company highly specialized at developing drugs to treat gastrointestinal and related diseases. The company's lead clinical candidate, Intestinal Trefoil Factor (ITF), is being developed for the treatment of oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and/or radiotherapy. Phase II clinical results are expected to be released in the 1st half of 2008. The GI Company also has pre-clinical development programs in enteritis/proctitis, inflammatory bowel disease, erosive gastroesophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis (NSAID induced), ulcerative colitis and corneal wound healing. For more information, visit www.thegicompany.com.

LaVoie Group to Attend JP Morgan's Annual Healthcare Conference Jan. 7-10, 2008

If you are interested in meeting us in San Francisco, please email dlavoie@lavoiegroup.com.

Donna LaVoie to Chair Panel Discussion at BIO 2008

Donna LaVoie will chair a panel discussion during the BIO 2008 International Convention from June 17-20, 2008 with leading industry IR experts. To learn more about this panel titled, "Investor Relations Practices Across Various Market-Cap Companies," please click [here](#).